Repligen Co. (NASDAQ:RGEN) Holdings Raised by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lifted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 4.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,632 shares of the biotechnology company’s stock after purchasing an additional 1,337 shares during the quarter. Mutual of America Capital Management LLC owned about 0.06% of Repligen worth $4,240,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Edgestream Partners L.P. bought a new stake in shares of Repligen during the second quarter valued at about $308,000. Renaissance Technologies LLC bought a new stake in shares of Repligen during the second quarter valued at about $5,320,000. Dimensional Fund Advisors LP grew its holdings in Repligen by 39.4% during the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after acquiring an additional 121,305 shares during the period. Envestnet Asset Management Inc. grew its holdings in Repligen by 0.7% during the second quarter. Envestnet Asset Management Inc. now owns 108,741 shares of the biotechnology company’s stock worth $13,708,000 after acquiring an additional 741 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its holdings in Repligen by 16.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 19,574 shares of the biotechnology company’s stock worth $2,467,000 after acquiring an additional 2,783 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on RGEN. Royal Bank of Canada reissued an “outperform” rating and issued a $190.00 price target on shares of Repligen in a research note on Wednesday, July 31st. UBS Group dropped their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Guggenheim began coverage on Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating on the stock. Finally, Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average price target of $188.38.

Repligen Price Performance

Shares of RGEN opened at $142.97 on Monday. The company has a market capitalization of $7.99 billion, a price-to-earnings ratio of 571.88, a P/E/G ratio of 4.14 and a beta of 0.94. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The business’s 50-day moving average is $147.30 and its 200-day moving average is $154.97.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The firm’s quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.53 EPS. Equities research analysts expect that Repligen Co. will post 1.45 EPS for the current fiscal year.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.